Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential.
Philippe Md PoteyAdriano G RossiChristopher D LucasDavid A DorwardPublished in: The Journal of pathology (2019)
Acute respiratory distress syndrome (ARDS) is the often fatal sequelae of a broad range of precipitating conditions. Despite decades of intensive research and clinical trials there remain no therapies in routine clinical practice that target the dysregulated and overwhelming inflammatory response that characterises ARDS. Neutrophils play a central role in the initiation, propagation and resolution of this complex inflammatory environment by migrating into the lung and executing a variety of pro-inflammatory functions. These include degranulation with liberation of bactericidal proteins, release of cytokines and reactive oxygen species as well as production of neutrophil extracellular traps. Although these functions are advantageous in clearing bacterial infection, the consequence of associated tissue damage, the contribution to worsening acute inflammation and prolonged neutrophil lifespan at sites of inflammation are deleterious. In this review, the importance of the neutrophil will be considered, together with discussion of recent advances in understanding neutrophil function and the factors that influence them throughout the phases of inflammation in ARDS. From a better understanding of neutrophils in this context, potential therapeutic targets are identified and discussed. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Keyphrases
- acute respiratory distress syndrome
- oxidative stress
- extracorporeal membrane oxygenation
- mechanical ventilation
- respiratory failure
- clinical practice
- inflammatory response
- clinical trial
- liver failure
- reactive oxygen species
- intensive care unit
- pulmonary hypertension
- drug induced
- randomized controlled trial
- aortic dissection
- open label
- phase ii
- double blind